Cannabis Investors: Will Aleafia Health (TSX:ALEF) Stock Gain Momentum in December?

What next for Aleafia Health investors after an 80% decline in market value in the last 12 months?

| More on:
edit Jars of marijuana

Image source: Getty Images

Shares of Canada-based cannabis company Aleafia Health (TSX:ALEF) are trading at $0.66 at writing. The stock went public back in July 2011 at $0.30 per share. The legalization of cannabis for recreational use drove the stock to record highs of $3.11 per share in October 2018.

This means that investors have lost close to 80% in market value in the past year. The overall weakness in the cannabis space coupled with lower than estimates sales figures for marijuana companies has destroyed investor wealth in 2019.

But has Aleafia Health stock bottomed out? And will shares move higher as we inch closer to 2020?

A look at Aleafia’s production capacities

Aleafia Health is a vertically integrated marijuana company with medical clinic, cannabis cultivation, and research & development operations. Aleafia has a few indirect wholly-owned subsidiaries through which the former owns three production facilities.

Aleafia’s Ontario facilities are located in Blackrock, Niagara, and Paris. The Niagara facility is a 160,000 square feet space with an annual cultivation capacity of 25,000 kilograms. Its Blackrock facility has a cultivation area spanning 3.74 million square feet with an annual cultivation capacity of 103,000 kilograms.

The Paris facility is Aleafia’s smallest with a cultivation space of 17,000 square feet and an annual production capacity of 1,500 kilograms. Although Aleafia can cultivate 129,500 kilograms of dried cannabis flowers, only 32,600 kilograms can be produced at licensed and operational facilities, while the rest can be produced once it receives approval from Health Canada.

Aleafia needs to be wary of oversupply

While Aleafia is rapidly scaling production, it needs to be wary of oversupply that’s currently impacting the retail marijuana space. Due to the slow roll out of retail stores in major Canadian provinces, many cannabis companies have been grappling with rising inventory levels.

Aleafia’s inventory value has risen from $4.25 million in the June quarter to $7.81 million in the September quarter. Inventory value rose by 84% compared to a 29% rise in revenue on a sequential basis. While demand has been constrained due to the aforementioned issues, Aleafia has managed to grow sales at a robust pace.

In the third quarter of 2019, Aleafia sales were up 239% year over year to $4.95 million. In the first nine months of 2019, sales were up 285% year over year at $10.32 million. Analysts expect company sales to rise from $3.33 million in 2018 to $15.4 million in 2019.

Company sales are expected to rise to $70.1 million in 2020 and $163 million in 2020. With the estimated rise in sales, analysts also estimate a robust expansion in Aleafia’s profit margins.

Aleafia’s EBITDA is slated to decline from -$7.37 million in 2018 to -$18.8 million in 2019. However, analysts expect it to be EBITDA positive by 2020 with reported EBITDA of $2.88 million in next year and $47.9 million in 2021, suggesting that Aleafia’s EBITDA margin will reach a healthy 29.4% by 2021.

Similar to other cannabis companies, we’ve seen that Aleafia is investing heavily in capital expenditure. The cannabis companies will be impacted by near-term oversupply issues.

However, the growth story for marijuana producers remains intact as the addressable market continues to expand in the recreational and medical marijuana space.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »